Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Sage Therapeutics drug reduces postpartum depression in two late-stage clinical trials

  • Adam Feuerstein

By Adam Feuerstein Nov. 9, 2017

Reprints
Silence Sucks
Sage Therapeutics

Updated with new information.

Sage Therapeutics (SAGE) reported positive results Thursday from two late-stage clinical trials of its lead drug brexanolone in women suffering from postpartum depression.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

How the drug industry uses fear of fentanyl to…
How the drug industry uses fear of fentanyl to extract more profit from naloxone
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Experts debate: Are we playing with fire when we…
Experts debate: Are we playing with fire when we edit human genes?
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

Recommended Stories